Business Wire

Study Uses Masimo Patient SafetyNet™ and rainbow Acoustic Monitoring® to Investigate the Incidence of Desaturation and Bradypnea in Postoperative Patients

Share

Masimo (NASDAQ: MASI) announced today that in a study recently published in the Journal of Clinical Monitoring and Computing, researchers at Nippon Medical School in Tokyo, Japan used Masimo Patient SafetyNet™ and rainbow Acoustic Monitoring® (RAM®), acoustic respiration rate monitoring with RRa®, as a centralized continuous monitoring system to identify the incidence and predictors of desaturation and bradypnea in postoperative patients – concluding that “Use of monitoring systems might provide a safety net for postoperative patients.”1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191120006062/en/

Masimo Patient SafetyNet™, Root® with Radius-7®, RRa®, and SET® (Photo: Business Wire)

Masimo Patient SafetyNet™, Root® with Radius-7®, RRa®, and SET® (Photo: Business Wire)

Patient SafetyNet is a supplemental remote monitoring, patient surveillance, and clinician notification system that works in conjunction with Masimo and third-party bedside monitoring devices to display near real-time data at central stations. RAM with RRa uses an acoustic transducer positioned on the patient’s neck to provide noninvasive, continuous respiration monitoring.

Hypothesizing that postoperative desaturation and bradypnea might occur even in non-ICU patients without serious complications, and in patients who did not undergo major surgery, Drs. Masashi Ishikawa and Atsuhiro Sakamoto set up a centralized postoperative monitoring system in the general ward to investigate how common these events are for such patients (and what might predict them). They analyzed demographic and monitoring data from 1,064 adult patients who underwent general anesthesia for various surgical procedures over a 4-month period. The patients were monitored using a pulse oximeter and an RRa sensor for at least 8 hours after surgery, data which were automatically transferred to Patient SafetyNet.

From the data stored on the Patient SafetyNet, the researchers were able to retrospectively analyze the incidence of desaturation (defined as SpO2 < 90% for > 10 seconds) and bradypnea (defined as respiratory rate < 8 breaths/minute for > 2 minutes). They found that 12.1% of patients exhibited desaturation (244 events among 129 patients), with most occurring after the termination of oxygen administration, and 50.8% of the events occurring more than 8 hours after surgery. They found that 5.1% of the patients exhibited bradypnea (112 times among 54 patients), with 72.3% of the events occurring during oxygen supplementation, and with the greatest incidence within the first hour after surgery. Age, body mass index, and current smoking status were significant risk factors for desaturation. Sleep apnea syndrome and postoperative opioid administration were significant risk factors for bradypnea. Age and postoperative opioid administration were significant risk factors for the combination of desaturation and bradypnea.

The researchers concluded, “Our study suggests that use of a continuous and centralized respiratory monitoring system for overnight postoperatively is desirable for postoperative management in the general ward, which would likely improve the safety of postoperative patients, especially those with risk factors for respiratory depression.”

The researchers commented on a number of methods of respiratory rate monitoring, stating, “Continuous and centralized monitoring of oxygen saturation and respiratory rate can detect respiratory depression before it results in critical events such as cardiac arrest. Several methods of respiratory rate monitoring are currently used, including manual counting of breaths by a caregiver, capnography, and transthoracic impedance measurement. Manual counting of breaths (such as auscultation) is an intermittent, labor-intensive and unreliable method. Capnography provides accurate and continuous monitoring, but requires a nasal or facial interface, which can be uncomfortable and may lead to failure if the interface is moved. Transthoracic impedance is non-invasive and can detect respiratory efforts, but is unable to detect alveolar hypoventilation caused by airway obstruction.”2-6

Additionally, the researchers commented on RAM with RRa, the respiratory rate monitoring method used in the current study, and referenced another study in which RRa and capnography were compared, stating: “RRa is an acoustic monitoring device that continuously measures respiratory rate, and is as accurate as capnography in extubated patients.7 Patient activities, such as talking, coughing and crying, affect the results of both RRa and capnography. The measurement errors during these activities are, however, not clinically relevant because they require that the patients are awake and breathing. Further, the RRa sensor appears to be well-tolerated and no more subject to error than capnography.7 RRa was found to be a reliable device and had fewer complications in this study.”

@MasimoInnovates | #Masimo

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.8 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,9 improve CCHD screening in newborns,10 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.11-13 Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world,14 and is the primary pulse oximetry at 9 of the top 10 hospitals according to the 2019-20 U.S. News and World Report Best Hospitals Honor Roll.15 Masimo continues to refine SET® and in 2018, announced that SpO2 accuracy on RD SET® sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2 values they rely on accurately reflect a patient’s physiological status. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7® and Radius PPG™, portable devices like Rad-67™, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital automation and connectivity solutions are centered around the Iris® platform, and include Iris Gateway®, Patient SafetyNet, Replica™, Halo ION™, UniView™, and Doctella™. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.

ORi and RPVi have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

  1. Ishikawa M and Sakamoto A. Postoperative desaturation and bradypnea after general anesthesia in non-ICU patients: a retrospective evaluation. J Clin Monit Comput. 2 Mar 2019. https://doi.org/10.1007/s10877-019-00293-0.
  2. Petterson MT, Begnoche VL, and Graybeal JM. The effect of motion on pulse oximetry and its clinical significance. Anesth Analg. 2007;105(6 Suppl):78–84.
  3. Wilkinson JN, and Thanawala VU. Thoracic impedance monitoring of respiratory rate during sedation—is it safe? Anaesthesia. 2009;64(4):455–6.
  4. Cohen KP, Ladd WM, Beams DM, Sheers WS, Radwin RG, Tompkins WJ, and Webster JG. Comparison of impedance and inductance ventilation sensors on adults during breathing, motion, and simulated airway obstruction. IEEE Trans Biomed Eng. 1997;44(7):555–66.
  5. Drummond GB, Nimmo AF, and Elton RA. Thoracic impedance used for measuring chest wall movement in postoperative patients. Br J Anaesth. 1996;77(3):327–32.
  6. Brouillette RT, Morrow AS, Weese-Mayer DE, and Hunt CE. Comparison of respiratory inductive plethysmography and thoracic impedance for apnea monitoring. J Pediatr. 1987;111(3):377–83.
  7. Mimoz O, Benard T, Gaucher A, Frasca D, and Debaene B. Accuracy of respiratory rate monitoring using a non-invasive acoustic method after general anaesthesia. Br J Anaesth. 2012 May;108(5):872–5.
  8. Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
  9. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
  10. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
  11. Taenzer AH et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
  12. Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
  13. McGrath SP et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
  14. Estimate: Masimo data on file.
  15. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo Patient SafetyNet™ and RRa®. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo Patient SafetyNet and RRa, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Contact information

Masimo
Evan Lamb
949-396-3376
elamb@masimo.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCL Technologies Honors Global Goodwill Champions at the 2020 World Economic Forum in Davos24.1.2020 12:47:00 EETPress release

HCL Technologies (HCL), a leading global technology company, today presented its Wave Maker Awards 2020, commemorating global goodwill champions from around the world. The award ceremony, which was held at the HCL Pavilion in Davos, celebrated organizations and individuals passionately committed to such noble causes as diversity & inclusion, education & community upliftment, environment & sustainability, and technology for change. Special guest at the awards was Australian cricket legend Glenn McGrath, who is also founder of the McGrath Foundation, which provides support for Australian women diagnosed with breast cancer and their families. The award recipients were; Lois Auta, Founder and Executive Director of Cedar Seed Foundation, which supports persons with disabilities to participate in all aspects of life; Chido Govera, Founder and Director of The Future of Hope Foundation (TFoHF), which supports marginal and vulnerable members of society through entrepreneurial and self-developme

Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria24.1.2020 09:00:00 EETPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the decision to pause dosing patients in the global Phase III (PVO-1A-301) study designed to evaluate the efficacy and safety of palovarotene in patients with fibrodysplasia ossificans progressiva (FOP), as well as the ongoing Phase II (PVO-1A-202/204) extension studies. In both the Phase III and Phase II extension studies, palovarotene is dosed both chronically (daily) and episodically (during flare-ups). The decision to pause dosing patients in the trial is based on results of a futility analysis reviewed by the Independent Data Monitoring Committee (IDMC) as part of the prespecified interim analysis. The results of a futility analysis indicated that the Phase III FOP trial was unlikely to meet its primary efficacy endpoint (annualized change in new HO volume as compared with Natural History Studyi) upon completion. Despite the results of the prespecified interim analysis, signals of encouraging therapeutic activity w

Amazentis Announces the Launch of Timeline™ Cellular Nutrition at the World Economic Forum in Davos23.1.2020 23:56:00 EETPress release

Amazentis announces the debut of Timeline, a next generation nutrition product designed to promote healthy aging, as part of the Swiss Food & Nutrition Valley in the House of Switzerland at the World Economic Forum in Davos, Switzerland. Given the increase in the aging population globally -- according to a 2019 Deutsche Bank study, there are more people on Earth older than sixty five than younger than five for the first time -- it is imperative for consumers to take proactive measures to maintain a high quality of life, for as long as they live. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200123005820/en/ (Photo: Business Wire) Timeline contains the proprietary nutrient Mitopure™, a highly pure form of Urolithin A. After a decade of rigorous research by leading scientists around the world, Mitopure has been shown to help counter age-associated cellular and muscular decline by revitalizing the mitochondria, the powerplants

Lionbridge Names Corinne Saunders as Managing Director, EMEA23.1.2020 21:00:00 EETPress release

Today, Lionbridge, a global leader in localization and data training services, announced that former Wolters Kluwer executive Corinne Saunders has joined the company as managing director of EMEA. Lionbridge currently has 51 offices in 26 countries around the world; Saunders will oversee EMEA sales, account management, and marketing operations. “Europe represents a large portion of our overall business and will continue to be a growth area for our AI and localization businesses. I am very happy that Corinne is coming onboard to lead our efforts across EMEA,” says Lionbridge Chief Executive Officer John Fennelly. “Throughout her career, she’s shown an exceptional ability for driving innovation and understanding customer needs.” While at Wolters Kluwer, Saunders served as chief executive officer for emerging and developing markets. Saunders will work from Brussels, Belgium. About Lionbridge Lionbridge partners with brands to break barriers and build bridges all over the world. For more th

President Bill Clinton to Keynote 2020 World Patient Safety, Science & Technology Summit23.1.2020 20:34:00 EETPress release

President Bill Clinton, the 42nd President of the United States, will be the closing keynote speaker at the Patient Safety Movement Foundation’s 2020 World Patient Safety, Science & Technology Summit. The 8th annual Summit will be held in Huntington Beach, California, beginning with a Pre-Summit Symposium on Thursday, March 5th. At the 2020 Summit, hospital leaders, medical and information technology innovators, patient advocates, policy makers and government officials collaborate and discuss best practices solutions to eliminate preventable patient deaths in hospitals around the world. The event is co-convened with the International Society for Quality in Health Care (ISQua), the American Society of Anesthesiologists and the European Society of Anaesthesiology. The 2020 Summit is scheduled for March 5 – 7th, 2020, at the Waterfront Beach Resort in Huntington Beach, California. For more information about the 2020 World Patient Safety, Science & Technology Summit, visit http://patientsa

Covantis initiative announces technology partner - ConsenSys23.1.2020 18:00:00 EETPress release

The founding members of the Covantis initiative, which aims to modernize global trade operations, have announced the selection of ConsenSys, a market-leading Ethereum blockchain technology company, as the lead technology partner to develop its transformative platform. “The founders set up a robust selection process, including a two week hackathon, to ensure that we chose the right technology partner to meet our industry’s needs,” said Stefano Rettore, independent advisor to the project. “ConsenSys presented prototypes that demonstrated excellence in its field and has a track record of using blockchain technology to digitize processes in the commodity trade finance industry. We are confident this partnership will allow us to build a first-class product, centered around unparalleled functionality, security and privacy.” ConsenSys will leverage its enterprise-ready blockchain solutions and services, including PegaSys Orchestrate, Kaleido and MythX to build the blockchain network on Ethere

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom